Skip to content

Study · Randomized controlled trial · n = 72 · 2020

6 results

Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: A double-blind, randomized, placebo-controlled study.

Elkind-Hirsch KE, Shaler D, Harris R

Journal of diabetes and its complications1 Feb 2020Cited by 30 (Europe PMC)

PMID32046931 (opens in a new tab)DOI10.1016/j.jdiacomp.2020.107548 (opens in a new tab)PepBankPUB-32046931
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In overweight women with recent gestational diabetes, liraglutide plus metformin improved mean blood glucose more than metformin plus placebo.

    In plain wordsIn overweight women with recent gestational diabetes, adding liraglutide to metformin improved blood sugar more than metformin with placebo.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedMean blood glucose
    Study

    n = 72

    Comparator
    Metformin plus placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg · subcutaneous · 84 weeksAs given in this study (human).

    Source sentences

    Summary
    MET-LIRA therapy was significantly better in improving MBG and insulin sensitivity indices
    1 context sentence
    Summary · context
    Women (n = 153; body mass index (BMI) ≥25 kg/m2; 18-45 y; GDM within 12 months) with metabolic abnormalities were randomized to MET-LIRA (MET-2000 mg, LIRA 1.8 mg SC QD) or MET-P (MET-2000 mg, Placebo QD).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In overweight women with recent gestational diabetes, liraglutide plus metformin increased the OGTT insulin sensitivity index more than metformin plus placebo.

    In plain wordsIn overweight women with recent gestational diabetes, adding liraglutide to metformin improved insulin sensitivity more than metformin with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseInsulin sensitivity index (OGTT)
    Study

    n = 72

    Comparator
    Metformin plus placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg · subcutaneous · 84 weeksAs given in this study (human).

    Source sentences

    Summary
    MET-LIRA therapy was significantly better in improving MBG and insulin sensitivity indices [SIOGTT MET-LIRA from 4.6 (3.2) to 5.9 (2.9) vs. MET-P 5.5 (3.0) to 5.4 (3.2)]
    1 context sentence
    Summary · context
    Women (n = 153; body mass index (BMI) ≥25 kg/m2; 18-45 y; GDM within 12 months) with metabolic abnormalities were randomized to MET-LIRA (MET-2000 mg, LIRA 1.8 mg SC QD) or MET-P (MET-2000 mg, Placebo QD).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In overweight women with recent gestational diabetes, liraglutide plus metformin reduced body weight and BMI more than metformin plus placebo.

    In plain wordsIn overweight women with recent gestational diabetes, adding liraglutide to metformin lowered weight and BMI more than metformin with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody mass index
    Study

    n = 72

    Comparator
    Metformin plus placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg · subcutaneous · 84 weeksAs given in this study (human).

    Measurements

    BMI
    33.8 kg/m2
    MET-LIRA after therapy

    Source sentences

    Summary
    and reducing BW and central adiposity [BMI MET-LIRA from 37.2 (8.3) to 33.8 (5.2) vs MET-P 33.8(5.2) to 32.8(6)]
    1 context sentence
    Summary · context
    Women (n = 153; body mass index (BMI) ≥25 kg/m2; 18-45 y; GDM within 12 months) with metabolic abnormalities were randomized to MET-LIRA (MET-2000 mg, LIRA 1.8 mg SC QD) or MET-P (MET-2000 mg, Placebo QD).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In overweight women with recent gestational diabetes, liraglutide plus metformin reduced central adiposity more than metformin plus placebo.

    In plain wordsIn overweight women with recent gestational diabetes, adding liraglutide to metformin reduced belly fat more than metformin with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseCentral adiposity
    Study

    n = 72

    Comparator
    Metformin plus placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg · subcutaneous · 84 weeksAs given in this study (human).

    Source sentences

    Summary
    and reducing BW and central adiposity [BMI MET-LIRA from 37.2 (8.3) to 33.8 (5.2) vs MET-P 33.8(5.2) to 32.8(6)]
    1 context sentence
    Summary · context
    Women (n = 153; body mass index (BMI) ≥25 kg/m2; 18-45 y; GDM within 12 months) with metabolic abnormalities were randomized to MET-LIRA (MET-2000 mg, LIRA 1.8 mg SC QD) or MET-P (MET-2000 mg, Placebo QD).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In overweight women with recent gestational diabetes, triglycerides fell with liraglutide plus metformin but not with metformin plus placebo.

    In plain wordsIn overweight women with recent gestational diabetes, triglycerides fell with liraglutide plus metformin but not with metformin plus placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseTriglycerides
    Study

    n = 72

    Comparator
    Metformin plus placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    1.8 mg · subcutaneous · 84 weeksAs given in this study (human).

    Source sentences

    Summary
    MET-LIRA therapy but not MET-P decreased triglycerides (TRG) and TRG/high density lipoprotein cholesterol (HDL-C) ratios.
    1 context sentence
    Summary · context
    Women (n = 153; body mass index (BMI) ≥25 kg/m2; 18-45 y; GDM within 12 months) with metabolic abnormalities were randomized to MET-LIRA (MET-2000 mg, LIRA 1.8 mg SC QD) or MET-P (MET-2000 mg, Placebo QD).
  6. 06HumanRandomized controlled trialEfficacy outcome

    In overweight women with recent gestational diabetes, the triglyceride to HDL cholesterol ratio fell with liraglutide plus metformin but not with metformin plus placebo.

    In plain wordsIn overweight women with recent gestational diabetes, a blood fat ratio fell with liraglutide plus metformin but not with metformin plus placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseTriglyceride to HDL cholesterol ratio
    Study

    n = 72

    Comparator
    Metformin plus placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    1.8 mg · subcutaneous · 84 weeksAs given in this study (human).

    Source sentences

    Summary
    MET-LIRA therapy but not MET-P decreased triglycerides (TRG) and TRG/high density lipoprotein cholesterol (HDL-C) ratios.
    1 context sentence
    Summary · context
    Women (n = 153; body mass index (BMI) ≥25 kg/m2; 18-45 y; GDM within 12 months) with metabolic abnormalities were randomized to MET-LIRA (MET-2000 mg, LIRA 1.8 mg SC QD) or MET-P (MET-2000 mg, Placebo QD).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01234649

Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)

Woman'sn = 15311 Aug 2011 to 14 Jun 2019

Gestational Diabetes Mellitus · Type 2 Diabetes Mellitus · Metabolic Syndrome · Impaired Glucose Tolerance · Disorder of Glucose Regulation

Trial pageClinicalTrials.govUpdated 26 Jul 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.